AR105124A1 - Tratamiento de carcinoma de la línea media nut - Google Patents
Tratamiento de carcinoma de la línea media nutInfo
- Publication number
- AR105124A1 AR105124A1 ARP160101908A ARP160101908A AR105124A1 AR 105124 A1 AR105124 A1 AR 105124A1 AR P160101908 A ARP160101908 A AR P160101908A AR P160101908 A ARP160101908 A AR P160101908A AR 105124 A1 AR105124 A1 AR 105124A1
- Authority
- AR
- Argentina
- Prior art keywords
- cycle
- patient
- formulas
- drug
- nut line
- Prior art date
Links
- 201000009030 Carcinoma Diseases 0.000 title abstract 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 abstract 2
- 102100022338 Integrin alpha-M Human genes 0.000 abstract 2
- 102000007999 Nuclear Proteins Human genes 0.000 abstract 2
- 108010089610 Nuclear Proteins Proteins 0.000 abstract 2
- 229940125763 bromodomain inhibitor Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000002381 testicular Effects 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
- G01N2333/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562185203P | 2015-06-26 | 2015-06-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR105124A1 true AR105124A1 (es) | 2017-09-06 |
Family
ID=56409188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160101908A AR105124A1 (es) | 2015-06-26 | 2016-06-24 | Tratamiento de carcinoma de la línea media nut |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20180193350A1 (enExample) |
| EP (1) | EP3314005A1 (enExample) |
| JP (1) | JP2018520124A (enExample) |
| KR (1) | KR20180035785A (enExample) |
| CN (1) | CN107787227A (enExample) |
| AR (1) | AR105124A1 (enExample) |
| AU (1) | AU2016283020A1 (enExample) |
| BR (1) | BR112017028178A2 (enExample) |
| CA (1) | CA2989313A1 (enExample) |
| HK (1) | HK1252062A1 (enExample) |
| IL (1) | IL256186A (enExample) |
| MA (1) | MA42249A (enExample) |
| MX (1) | MX2017016337A (enExample) |
| WO (1) | WO2016210275A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2799403C (en) | 2010-05-14 | 2020-01-21 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating leukemia |
| HUE031073T2 (en) | 2010-05-14 | 2017-06-28 | Dana Farber Cancer Inst Inc | Thieno triazolo-diazepine compounds for the treatment of neoplasia |
| RU2016122654A (ru) | 2013-11-08 | 2017-12-14 | Дана-Фарбер Кэнсер Инститьют, Инк. | Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка |
| CA2940472A1 (en) | 2014-02-28 | 2015-09-03 | Tensha Therapeutics, Inc. | Treatment of conditions associated with hyperinsulinaemia |
| EA033325B1 (ru) | 2014-10-27 | 2019-09-30 | Тэнша Терапеутикс, Инк. | Ингибиторы бромодомена |
| WO2024123929A1 (en) * | 2022-12-06 | 2024-06-13 | Bioventures, Llc | Development of potent dual hdac/brd4 inhibitors |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| CN101910182B (zh) | 2007-12-28 | 2013-07-17 | 田边三菱制药株式会社 | 抗癌剂 |
| GB0919431D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| EP3050885B1 (en) | 2009-11-05 | 2017-10-18 | GlaxoSmithKline LLC | Benzodiazepine bromodomain inhibitor |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919426D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| ES2652304T3 (es) | 2009-11-05 | 2018-02-01 | Glaxosmithkline Llc | Compuesto de benzodiacepina novedoso |
| HUE031073T2 (en) | 2010-05-14 | 2017-06-28 | Dana Farber Cancer Inst Inc | Thieno triazolo-diazepine compounds for the treatment of neoplasia |
| JP5715241B2 (ja) * | 2010-05-14 | 2015-05-07 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法 |
| WO2011161031A1 (en) | 2010-06-22 | 2011-12-29 | Glaxosmithkline Llc | Benzotriazolodiazepine compounds inhibitors of bromodomains |
| WO2012075456A1 (en) | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals | Bromodomain inhibitors and uses thereof |
| AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| EP2705039B1 (en) | 2011-05-04 | 2017-07-26 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| EP2721031B1 (en) | 2011-06-17 | 2016-01-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| TWI602820B (zh) | 2012-06-06 | 2017-10-21 | 星宿藥物公司 | 溴域抑制劑及其用途 |
| CA2940472A1 (en) | 2014-02-28 | 2015-09-03 | Tensha Therapeutics, Inc. | Treatment of conditions associated with hyperinsulinaemia |
-
2016
- 2016-06-24 AU AU2016283020A patent/AU2016283020A1/en not_active Abandoned
- 2016-06-24 MA MA042249A patent/MA42249A/fr unknown
- 2016-06-24 CA CA2989313A patent/CA2989313A1/en not_active Abandoned
- 2016-06-24 HK HK18111394.9A patent/HK1252062A1/zh unknown
- 2016-06-24 JP JP2017563973A patent/JP2018520124A/ja active Pending
- 2016-06-24 EP EP16738292.8A patent/EP3314005A1/en not_active Withdrawn
- 2016-06-24 US US15/739,905 patent/US20180193350A1/en not_active Abandoned
- 2016-06-24 KR KR1020187000569A patent/KR20180035785A/ko not_active Withdrawn
- 2016-06-24 WO PCT/US2016/039270 patent/WO2016210275A1/en not_active Ceased
- 2016-06-24 AR ARP160101908A patent/AR105124A1/es unknown
- 2016-06-24 MX MX2017016337A patent/MX2017016337A/es unknown
- 2016-06-24 CN CN201680036201.4A patent/CN107787227A/zh active Pending
- 2016-06-24 BR BR112017028178A patent/BR112017028178A2/pt not_active Application Discontinuation
-
2017
- 2017-12-07 IL IL256186A patent/IL256186A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017028178A2 (pt) | 2018-08-28 |
| CN107787227A (zh) | 2018-03-09 |
| MX2017016337A (es) | 2018-11-22 |
| AU2016283020A1 (en) | 2018-01-04 |
| MA42249A (fr) | 2018-05-02 |
| KR20180035785A (ko) | 2018-04-06 |
| IL256186A (en) | 2018-02-28 |
| WO2016210275A1 (en) | 2016-12-29 |
| EP3314005A1 (en) | 2018-05-02 |
| CA2989313A1 (en) | 2016-12-29 |
| US20180193350A1 (en) | 2018-07-12 |
| HK1252062A1 (zh) | 2019-05-10 |
| JP2018520124A (ja) | 2018-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR105124A1 (es) | Tratamiento de carcinoma de la línea media nut | |
| CY1122648T1 (el) | Διαδικασια για την παρασκευη συνθεσεων που περιεχουν υαλουρονικο οξυ και υδροχλωρικη μεπιβακαϊνη | |
| EA201790398A1 (ru) | Способы лечения заболевания печени | |
| EA201790195A1 (ru) | Способы лечения рака с применением ингибиторов tigit и противораковых агентов | |
| CY1120049T1 (el) | (2s)-ν-[(1s)-1-κυανο-2-φαινυλαιθυλ]-1,4-οξαζεπαν-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης i | |
| AR109452A1 (es) | Formulación farmacéutica de un inhibidor de lsd1 y método de tratamiento | |
| MX390795B (es) | Inhibidores de transportador de monoamina vesicular tipo 2 (vmat2) para tratar enfermedades o trastornos neurologicos. | |
| MX2017014584A (es) | Inhibidores heterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer. | |
| EA201692285A8 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
| EA201691151A1 (ru) | Соединения для лечения пациентов с ros1-мутантными раковыми клетками | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| MX378664B (es) | Composiciones farmaceuticas que comprenden un farmaco antipsicotico y un inhibidor de la isoforma 2 del transportador de monomina vesicular (vmat2) y sus usos. | |
| EA201791993A1 (ru) | Способы лечения протеинопатий | |
| DOP2018000196A (es) | Metodos para tratar la depresion con antagonistas del receptor de orexina-2 | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| EA201790223A1 (ru) | Водный препарат, содержащий парацетамол и ибупрофен | |
| MX2021000363A (es) | Uso de estimuladores de la guanilato ciclasa soluble (sgc) para el tratamiento de trastornos mitocondriales. | |
| EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| MX2018001720A (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos. | |
| EA201792264A1 (ru) | Способы лечения воспалительных заболеваний | |
| MY203831A (en) | Treatment and diagnosis of inflammatory disorders | |
| EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
| EA201792121A1 (ru) | Фармацевтические солевые формы ингибитора семикарбазидчувствительной аминоксидазы (ssao) | |
| EA201992414A1 (ru) | Комбинация nk1-антагониста и способ лечения синуклеинопатий |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |